(Q44963511)

English

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Frieder Bauss

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Robert K Schenk

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Stefan Hört

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Bernd Müller-Beckmann

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Gisbert Sponer

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Journal of Pharmacological and Toxicological Methods

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

25-34

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Removal of tibial marrow induces increased formation of bone and cartilage in rat mandibular condyle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Development and characterization of a polyclonal antiserum-based radioimmunoassay for dog osteocalcin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

The long-term skeletal effects of EHDP in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

The influence of dichloromethylene bisphosphonate on the healing of a long bone fracture, composition of bone mineral and histology of bone in the rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effect of EHDP on fracture healing in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effect of alendronate on fracture healing and bone remodeling in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Pattern of gene expression following rat tibial marrow ablation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

The bone "quality" problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2003.11.003

7 January 2021

Identifiers

10.1016/J.VASCN.2003.11.003

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44963511&oldid=2059776811"